Literature DB >> 16470891

Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors.

Catherine M Alfano1, Bonnie A McGregor, Alan Kuniyuki, Bryce B Reeve, Deborah J Bowen, Kathy B Baumgartner, Leslie Bernstein, Rachel Ballard-Barbash, Kathleen E Malone, Patricia A Ganz, Anne McTiernan.   

Abstract

Hormone-related symptoms are common in breast cancer survivors and many aspects of these symptoms are currently under study. Reliable and valid assessment tools are needed to successfully study hormone-related symptoms in breast cancer survivors; however, no gold standard currently exists for measuring these symptoms. This study evaluated the psychometric properties of a shortened version of the Breast Cancer Prevention Trial (BCPT) symptom checklist in a sample of 803 breast cancer survivors. Principal factor analysis with Promax oblique rotation revealed a five-factor structure, identifying five separate hormone-related symptoms scales: vasomotor symptoms, urinary incontinence, cognitive/mood changes, vaginal symptoms, and weight gain/appearance concern. Hormone-related symptom scale scores differed by demographic and clinical characteristics according to expectations, suggesting that these five scales from the shortened BCPT checklist are reasonably reliable and valid. Symptom scale scores were only weakly correlated with health-related quality of life scores; however, the pattern of results generally supported the validity of the symptom scales. This study adds to the evidence that breast cancer survivors experience a significant number of hormone-related symptoms. Future clinical trials and quality of life and symptom management intervention studies would benefit from accurate assessment of hormone-related symptoms with the five scales from the shortened BCPT checklist.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16470891      PMCID: PMC2996243          DOI: 10.1002/pon.1033

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  21 in total

Review 1.  Assessing the clinical significance of single items relative to summated scores.

Authors:  Jeff A Sloan; Neil Aaronson; Joseph C Cappelleri; Diane L Fairclough; Claudette Varricchio
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

2.  Oral contraceptives and the risk of breast cancer.

Authors:  Polly A Marchbanks; Jill A McDonald; Hoyt G Wilson; Suzanne G Folger; Michele G Mandel; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Giske Ursin; Brian L Strom; Sandra A Norman; Phyllis A Wingo; Ronald T Burkman; Jesse A Berlin; Michael S Simon; Robert Spirtas; Linda K Weiss
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

3.  The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer.

Authors:  Annette L Stanton; Coen A Bernaards; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2005-03-16       Impact factor: 13.506

4.  The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational results.

Authors:  Polly A Marchbanks; Jill A Mcdonald; Hoyt G Wilson; Nancy M Burnett; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Brian L Strom; Sandra A Norman; Linda K Weiss; Jonathan M Liff; Phyllis A Wingo; Ronald T Burkman; Suzanne G Folger; Jesse A Berlin; Dennis M Deapen; Giske Ursin; Ralph J Coates; Michael S Simon; Michael F Press; Robert Spirtas
Journal:  Ann Epidemiol       Date:  2002-05       Impact factor: 3.797

5.  Predictors of sexual health in women after a breast cancer diagnosis.

Authors:  P A Ganz; K A Desmond; T R Belin; B E Meyerowitz; J H Rowland
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

6.  Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.

Authors:  J E Bower; P A Ganz; K A Desmond; J H Rowland; B E Meyerowitz; T R Belin
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

7.  Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial.

Authors:  P A Ganz; G A Greendale; L Petersen; L Zibecchi; B Kahn; T R Belin
Journal:  J Natl Cancer Inst       Date:  2000-07-05       Impact factor: 13.506

8.  A prospective population-based study of menopausal symptoms.

Authors:  L Dennerstein; E C Dudley; J L Hopper; J R Guthrie; H G Burger
Journal:  Obstet Gynecol       Date:  2000-09       Impact factor: 7.661

9.  Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study.

Authors:  Patricia A Ganz; Katherine A Desmond; Beth Leedham; Julia H Rowland; Beth E Meyerowitz; Thomas R Belin
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

10.  Lifetime recreational exercise activity and risk of breast carcinoma in situ.

Authors:  Alpa V Patel; Michael F Press; Kathleen Meeske; Eugenia E Calle; Leslie Bernstein
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

View more
  27 in total

1.  Psychometric evaluation of the Brief Cancer Impact Assessment among breast cancer survivors.

Authors:  Catherine M Alfano; Bonnie A McGregor; Alan Kuniyuki; Bryce B Reeve; Deborah J Bowen; Ashley Wilder Smith; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash; Kathleen E Malone; Patricia A Ganz; Anne McTiernan
Journal:  Oncology       Date:  2006-06-29       Impact factor: 2.935

Review 2.  Urinary symptoms in breast cancer: a systematic review.

Authors:  Kristine A Donovan; Alice R Boyington; Roohi Ismail-Khan; Jean F Wyman
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

3.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Authors:  Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley
Journal:  Lancet Oncol       Date:  2015-06-16       Impact factor: 41.316

4.  Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life.

Authors:  Catherine M Alfano; Kenneth L Lichstein; Gregory S Vander Wal; Ashley Wilder Smith; Bryce B Reeve; Anne McTiernan; Leslie Bernstein; Kathy B Baumgartner; Rachel Ballard-Barbash
Journal:  Breast Cancer Res Treat       Date:  2011-05-13       Impact factor: 4.872

5.  Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.

Authors:  Tera L Fazzino; Jennifer Klemp; Christie Befort
Journal:  Breast Cancer Res Treat       Date:  2017-12-22       Impact factor: 4.872

6.  A self-report instrument that describes urogenital atrophy symptoms in breast cancer survivors.

Authors:  Joanne Lester; Linda Bernhard; Nancy Ryan-Wenger
Journal:  West J Nurs Res       Date:  2010-12-20       Impact factor: 1.967

7.  Weight, inflammation, cancer-related symptoms and health related quality of life among breast cancer survivors.

Authors:  Ikuyo Imayama; Catherine M Alfano; Marian L Neuhouser; Stephanie M George; Ashley Wilder Smith; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Ching-Yun Wang; Catherine Duggan; Rachel Ballard-Barbash; Anne McTiernan
Journal:  Breast Cancer Res Treat       Date:  2013-07       Impact factor: 4.872

8.  Association between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery.

Authors:  Susan W Wesmiller; Catherine M Bender; Susan M Sereika; Gretchen Ahrendt; Marguerite Bonaventura; Dana H Bovbjerg; Yvette Conley
Journal:  Oncol Nurs Forum       Date:  2014-03-01       Impact factor: 2.172

9.  Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report.

Authors:  Kathleen Meeske; Ashley Wilder Smith; Catherine M Alfano; Bonnie A McGregor; Anne McTiernan; Kathy B Baumgartner; Kathleen E Malone; Bryce B Reeve; Rachel Ballard-Barbash; Leslie Bernstein
Journal:  Qual Life Res       Date:  2007-04-25       Impact factor: 4.147

10.  Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

Authors:  Karin Ribi; Weixiu Luo; Jürg Bernhard; Prudence A Francis; Harold J Burstein; Eva Ciruelos; Meritxell Bellet; Lorenzo Pavesi; Ana Lluch; Marilena Visini; Vani Parmar; Carlo Tondini; Pierre Kerbrat; Antonia Perelló; Patrick Neven; Roberto Torres; Davide Lombardi; Fabio Puglisi; Per Karlsson; Thomas Ruhstaller; Marco Colleoni; Alan S Coates; Aron Goldhirsch; Karen N Price; Richard D Gelber; Meredith M Regan; Gini F Fleming
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.